Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer major events at both 3 and 6 months compared to those receiving a placebo, often before most had reached the full target dose. A new analysis from the landmark SELECT trial reveals that semaglutide can quickly reduce the risk [...]from SciTechDaily https://ift.tt/3xe5QTL
